Serum protein fingerprint of patients with gastric cancer by SELDI technology

African Journal of Biotechnology

Volumn 9, Issue 15, 2010, Pages 2298-2304

  Liu, Chibo ^a   Wang, Haibao ^a   Pan, Chunqin ^a   Mou, Sihua ^a   Liang, Yong ^a  

^a TAIZHOU MUNICIPAL HOSPITAL   (China)

Author keywords

Biomarker; Gastric cancer; Proteomics; Seldi

Indexed keywords

BIOLOGICAL MARKER; PROTEIN;

ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEOMICS; SENSITIVITY AND SPECIFICITY; STOMACH ADENOCARCINOMA; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; UPREGULATION;

EID: 77951225092     PISSN: None     EISSN: 16845315     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA (2002). Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res. 62: 3609-3614.
2. Bhattacharyya S, Siegel ER, Petersen GM, Chari ST, Suva LJ (2004). Diagnosis of pancreatic cancer using serum proteomic profiling. Neoplasia, 6: 674-686.
3. Cho WC (2006). Research progress in SELDI-TOF MS and its clinical applications. Sheng Wu Gong Cheng Xue Bao. 22: 871-876.
4. Cho WC (2007). Proteomics technologies and challenges. Genomics Proteomics Bioinformatics. 5: 77-85.
5. Cho WC (2007).Contribution of oncoproteomics to cancer biomarker discovery. Mol.Cancer, 6: 25.
6. Cho WC, Cheng CH (2007). Oncoproteomics: current trends and future perspectives. Expert. Rev. Proteomics. 4: 401-410.
7. Cho WC, Yip TT, Ngan RK, Yip TT, Podust VN (2007) ProteinChip array profiling for identification of disease and chemotherapy-associated biomarkers of nasopharyngeal carcinoma. Clin. Chem. 53: 241-250.
8. Cho WC, Yip TT, Yip C, Yip V, Thulasiraman V (2004). Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin. Cancer Res. 10: 43-52.
9. Conrad TP, Hood BL, Issaq HJ, Veenstra TD (2004). Proteomic patterns as a diagnostic tool for early-stage cancer: a review of its progress to a clinically relevant tool. Mol. Diagn. 8: 77-85.
10. Dan A, Delmiro FR, Marios CP, Sergio AR, Mark H (2006). Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum. Lancet, 368: 1012-1021.
11. Ehmann M, Felix K, Hartmann D, Schnölzer M, Nees M (2007). Friess H. Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling. Pancreas, 34: 205-214.
12. Hanash S (2003). Disease proteomics. Nature, pp. 6-32.
13. Honda K, Hayashida Y, Umaki T, Okusaka T, Kosuge T (2005). Possible detection of pancreatic cancer by plasma protein profiling. Cancer Res. 65: 10613-10622.
14. Issaq HJ (2001. The role of separation science in proteomics research. E1ectrophoresis, 22: 3629-3638.
15. Issaq HJ, Veenstra TD, Conrads TP, Felschow D (2002). The SELDI- TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem. Biophys. Res. Commun. 292: 587-592.
16. Kodera Y, Ito S, Yamamura Y, Mochizuki Y, Fujiwara M, Hibi K, Ito K, Akiyama S, Nakao A (2003). Follow-up surveillance for recurrence after curative gastric cancer surgery lacks survival benefit. Ann. Surg. Oncol. 10: 898-902.
17. Koopmann J, Zhang Z, White N, Rosenzweig J, Fedarko N (2004). Serum diagnosis of pancreatic adenocarcinoma using surface- enhanced laser desorption and ionization mass spectrometry. Clin. Cancer Res. 10: 860-868.
18. Kozak KR, Amneus MW, Pusey SM, Su F, Luong MN (2003). Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips:potential use in diagnosis and prognosi. Proc. Natl. Acad. Sci. USA.100: 12343-12348.
19. Langbein S, Lehmann J, Harder A, Steidler A, Michel MS (2006). Protein profiling of bladder cancer using the 2D-PAGE and SELDI- TOF-MS technique. Technol. Cancer Res. Treat. 5: 67-72.
20. Latterich M, Abramovitz M, Leyland-Jones B (2008). Proteomics: new technologies and clinical applications. Eur. J. Cancer, 44: 2737-2741.
21. Leung WKL, Sung JJ (2002). Review article:intestinal metaplasia and gastric carcinogenesis. Aliment. Pharmacol.Ther.16: 1209-1216.
22. Linke T, Doraiswamy S, Harrison EH (2007). Rat plasma proteomics: effects of abundant protein depletion on proteomic analysis. J. Chromatogr B Analyt. Technol. Biomed. Life Sci. 849: 273-281
23. Liu CB, Liang Y, Pan CQ, Wang HB, Mou SH (2009). Proteome Study of Differential Protein Expression in HBV-related Primary Hepatic Carcinoma. Chem. J. Chin. Univ. 30: 1763-1766.
24. Malik G, Ward MD, Gupta SK, Trosset MW, Grizzle WE (2005). Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. Clin. Cancer Res. 11: 1073-1085.
25. Paradis V, Degos F, Dargère D, Pham N, Belghiti J (2005). Identification of a new marker of hepatocellu1ar carcinom a by serum protein profiling of patients with chronic liver diseases. Hepatology. 41: 40-47.
26. Petricoin EFL, Liotta LA (2004). SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr. Opin. Biotechnol. 15: 24-30.
27. Ren Y, He QY, Fan J, Jones B, Zhou Y (2004). The use of proteomics in the discovery of serum biomarkers from patients with severe acute respiratory syndrome. Proteomics, 4: 3477-3484.
28. Rodland KD (2004). Proteomics and cancer diagnosis the potential of mass spectrometry. Clin. Biochem. 37: 579-583.
29. Schneider J, Bitterlich N, Schulze G (2005). Improved sensitivity in the diagnosis of gastro-intestinal tumors by fuzzy logic-based tumor marker profiles including the tumor M2-PK. Anticancer Res. 25: 1507-1515.
30. Walsh PC (2003). Serum proteomic patterns for detection of prostate cancer. J. Urol. 169: p. 1592.
31. Wulfkuhle JD, Liotta LA, Petricoin EF (2003). Proteomic applications for the early detection of cancer. Nat. Rev. Cancer. 3: 267.
32. Yu Y, Chen S, Wang LS, Chen WL, Guo WJ (2005). Prediction of pancreatic cancer by serum biomarkers using surface-enhanced laser desorption/ionization-based decision tree classification. Oncology, 68: 79-86.
33. Zeidan BA, Townsend PA (2008). SELDI-TOF proteomic profiling of breast carcinomas identifies clinicopathologically relevant groups of patients similar to previously defined clusters from cDNA expression. Breast Cancer Res. 10: p. 107.